Title: Clinicopathologic Features of Non-Small Cell Lung Cancer with the EML4-ALK Fusion Gene

Running Title: EML4-ALK fusion gene in resected NSCLC

Authors: Tsuyoshi Takahashi,¹ Makoto Sonobe,¹ Masashi Kobayashi,¹ Akihiko Yoshizawa,² Toshi Menju,¹ Ei Nakayama,¹ Nobuya Mino,¹ Shotaro Iwakiri,¹ Kiyoshi Sato,¹ Ryo Miyahara,¹ Kenichi Okubo,¹ Toshiaki Manabe,² and Hiroshi Date¹

Authors’ Affiliations: ¹Department of Thoracic Surgery and ²Department of Diagnostic Pathology, Faculty of Medicine, Kyoto University, Kyoto, Japan

Corresponding Author: Makoto Sonobe, Department of Thoracic Surgery, Faculty of Medicine, Kyoto University. Shogoin-Kawara-cho 54, Sakyo-ku, Kyoto 606-8507, Japan.

Phone: +81-75-751-4975, Fax: +81-75-751-4974, E-mail: mysonobe@kuhp.kyoto-u.ac.jp

(CC: bridget@kuhp.kyoto-u.ac.jp, msonobe-ths@umin.ac.jp)

Key Words: EML4-ALK, non-small cell lung cancer (NSCLC), Epidermal growth factor receptor, KRAS, ERBB2
[Abstract]

**Background:** A fusion gene between the echinoderm microtubule-associated protein-like 4 (EML4) and the anaplastic lymphoma kinase (ALK) has recently been identified in non-small cell lung cancers (NSCLCs). We screened for EML4-ALK fusion genes and examined the clinicopathological and genetic characteristics of the fusion-harboring NSCLC tumors.

**Methods:** We examined 313 NSCLC samples from patients who underwent resection at our Hospital between May 2001 and July 2005. We screened for the fusion genes using the reverse transcription polymerase chain reaction (RT-PCR) assay and confirmed the results with direct sequencing. We also examined mutations in the epidermal growth factor receptor (EGFR), KRAS, and ERBB2 genes.

**Results:** Five EML4-ALK fusion genes were detected (four from 111 female samples and one from 202 male samples; 1.6% overall). All five genes were found in adenocarcinomas and accounted for 2.4% of the 211 adenocarcinoma samples. One EML4-ALK fusion was variant 1, and two were variant 3. In addition, we also found two new fusion variants. Patients with fusion-positive tumors were non-smokers or light smokers. Among the 211 adenocarcinomas, mutations in EGFR, KRAS, and ERBB2 were detected in 105, 29, and 7 tumors, respectively. Interestingly, all of the fusion-positive NSCLCs had no mutations within these genes.
Conclusions: The EML4-ALK fusion genes were observed predominantly in adenocarcinomas, in female or non-smoking populations. Additionally, the EML4-ALK fusions were mutually exclusive with mutations in the EGFR, KRAS, and ERBB2 genes.

[Introduction]

Primary lung cancer is the leading cause of cancer-related death in many industrialized countries. Although a combination of surgery, chemotherapy, and/or radiotherapy can be used to treat this disease, the prognosis for patients remains dismal. In an effort to develop new treatment strategies, several molecular-targeting drugs have recently been developed. It is known that epidermal growth factor receptor (EGFR) gene mutations are one of the causes of primary lung adenocarcinomas, and to some extent, tyrosine kinase inhibitors that target EGFR (e.g., gefitinib and erlotinib) have proven successful for controlling this disease.¹⁻¹¹ Therefore, the identification of the key oncogenes for lung cancer is a very important step toward the development of novel molecular-targeting agents. Interestingly, EGFR gene mutations have been revealed to be exclusive in adenocarcinomas, and most of these patients are from the Asian, female, non-smoker population.⁶⁻⁹, ¹¹⁻²², ²⁴ Gefitinib is most commonly applied to lung adenocarcinomas with these typical clinicopathological features.
These facts underscore the importance of discovering favorable clinicopathologic and genetic characteristics for each type of tyrosine kinase inhibitor therapy.

Recently, Soda and colleagues (2007) identified another type of tyrosine kinase with accelerated activity in a fusion gene between the echinoderm microtubule-associated protein-like 4 (EML4) and the anaplastic lymphoma kinase (ALK). Indeed, ALK kinase inhibitors have already been developed and have been reported to suppress the growth of EML4-ALK fusion positive cells. Thus, treatment with ALK inhibitors can be effective for non-small cell lung cancer (NSCLC) patients whose tumors contain an EML4-ALK fusion.

In this report, we examine the EML4-ALK fusion gene in a relatively large number of clinical samples, and investigate its clinicopathologic and genetic background, in order to identify useful information on patient selection for ALK inhibitor therapy.

[Materials and Methods]

Patients and sample collection

This study included 313 Japanese NSCLC patients (211 adenocarcinomas, 75 squamous cell carcinomas, 17 large cell carcinomas, and 10 other NSCLCs) who underwent
pulmonary resection at Kyoto University Hospital between May 2001 and July 2005. The pathological stage was evaluated according to the current international TNM staging system and the classification of the World Health Organization (WHO). Patient data were obtained from inpatient and outpatient medical records. All patients were followed-up (either to the time of death or through April 2009) using outpatient medical records and by letter or phone. The genetic analyses in the present study were approved by the Ethics Committee of our institute.

**Preparation of cDNA**

All of the tumor tissues were stored in RNAlater TissueProtect Tubes (Qiagen) immediately after pulmonary resections for RNA stabilization. Total RNA was extracted from specimens using the RNeasy Mini Kit (Qiagen), and the RNA extract was incubated with RNase-free DNase I (Qiagen) to remove contaminating DNA. Reverse-transcription of total RNA was performed using Ready-To-Go You-Prime First-Strand Beads (Amersham Bioscience) to generate cDNA.

**Detection of EML4-ALK fusion genes**

For detection of *EML4-ALK* fusion cDNAs, we performed reverse transcription polymerase chain reaction (RT-PCR) assays using the primer set described by Soda et al.\(^{23, 27}\)

5′-GTGCAGTGGTAGCATTCTTGGG-3′ (forward primer, on exon 13 of *EML4*) and
5'-TCTTGCCAGCAAAGCAGTAGTTGG-3' (reverse primer, on exon 21 of ALK). We also used the following primer set to detect other types of fusion transcripts consisting of the upper exons of EML4 and ALK: 5'-GTCAGCTCTTGAGTCACGAGTT-3' (forward primer, on exon 2 of EML4) and 5'-TCTTGCCAGCAAAGCAGTAGTTGG-3' (reverse primer, on exon 21 of ALK). Amplification was initiated by pre-incubation for 15 min at 95°C for the initial activation, followed by 35 cycles of: denaturation for 30 s at 95°C, primer annealing for 30 s at 66°C, and elongation for 1 min at 72°C using HotStar Taq Master Mix Kit (Qiagen). A 12µL aliquot of each reaction mixture was electrophoresed through a 2% agarose gel and stained by ethidium bromide for visualization under ultraviolet light. We used the primers 5'-ACAACAGCCTCAAGATCATCAG-3' (forward) and 5'-TCTTCTGGGTGGCAGTGATG-3' (reverse) to amplify the GAPDH gene as an internal control. GAPDH amplification was performed by pre-incubation for 10 min at 95°C for initial activation, followed by 35 cycles of: denaturation for 15 s at 94°C, primer annealing for 15 s at 59°C, and elongation for 15 s at 72°C.

**Detection of the mutations within the EGFR, KRAS, and ERBB2 genes**

As reported previously, we analyzed mutations in the EGFR (exons 18-21)\(^28\) and ERBB2 (exons 19-20) genes\(^30\) by the PCR-single strand conformational polymorphism (PCR-SSCP) technique. We also used a modified mutagenic restriction fragment length
polymorphism (PCR-RFLP) method to screen for mutations in codon 12 of the KRAS gene.28

**Histopathological analysis**

All of the surgical specimens were subjected to hematoxylin-eosin staining at the Department of Diagnostic Pathology of our hospital. Two board-certified pathologists independently reviewed the slides and performed diagnoses according to the 2004 WHO Classification of lung tumors.

[Results]

**Detection of the EML4-ALK fusion gene and analysis of fusion patterns**

Using RT-PCR, five fusion transcripts were detected (Fig. 1). The control GAPDH gene was amplified in all of the 313 samples (data not shown). The EML4 (exon 2)-ALK primer set amplified EML4-ALK fusion genes from all five of these patients (1-5), and the EML4 (exon 13)-ALK primer set amplified fusion genes from patients 1, 4, and 5. Direct sequence analysis confirmed the variant that was harbored by each tumor (Table 1). As a control, no gene was amplified by both primer sets from A549 cells, which do not carry the EML4-ALK fusion gene. Tumors from patient 4 carried a new fusion variant, which involved the fusion of full length exon 20 of EML4 and full length exon 20 of ALK with an 18-bp insertion sequence (5'-CTGACCACCCACCTGCAG-3') between the two exons. This inserted sequence is identical to the last 18-bp of ALK intron 19, which means that the break point of ALK was located at an upstream intron (Fig. 2A, B).
The tumor from patient 5 also had a novel transcript that involved a fusion between full-length *EML4* exon 17 and full-length *ALK* exon 20, with a 68-bp insertion sequence (5'-AGTCTTGCTCTGTCCTCCAGGCTGGAGTCAGGGCAATTTACACATTTCACATTCTAG TCGATCCTCAG-3') (Fig. 2A, C). Six sequences identical to the first part of the 14-bp sequence (5'-AGTCTTGCTCTGTC-3') were found in *ALK* introns: one sequence in intron 1, three in intron 3, one in intron 4, and one in intron 8. The reversed sequence (5'-GACAGAGCAAGACT-3') was also found in *ALK* introns: one each in introns 1, 3, 4, 5, and 26. Thus 11 copies of this 14-bp sequence were scattered throughout the *ALK* introns. One identical sequence to the middle part of the inserted sequence (5'-TCCAGGCTGGAGTCAGTCG-3', 19-bp) was also found in *ALK* intron 4, and its reversed sequence (5'-ACTGCACTCCAGCCTGGGA-3') was found in *ALK* intron 5. Interestingly, we found nineteen sequences resembling this middle inserted sequence in *ALK* introns, but they lacked the first thymidine and the last three nucleotides (i.e., 5'-CCCAGGCTGGAGTCG-3'). We also found twenty-one reversed copies of this sequence in *ALK* introns, thus *ALK* introns had 42 copies of 5'-CCCAGGCTGGAGTCG-3' and its reversed sequence. Among them, thirteen copies of 5'-CCCAGGCTGGAGTCG-3' and ten of the reversed sequence 5'-ACTGCACTCCAGCCTGGGA-3' were found. In *ALK* intron 19, one identical sequence to the last part of the inserted sequence (5'-GGCAATTACACATTTCATCGATCCTCAG-3', 35-bp) was also observed, and its reversed sequence (5'-CTGAGGATCGAATGATTGAAATGTGTAAATTGCC-3') was found in *ALK* intron 19. Thus, the inserted sequence of patient 5 consists of three *ALK* intron sequences. The *EML4-ALK* fusions from patients 4 and 5 resemble variant 3b, in which exon 6 of *EML* is fused to exon 20 of *ALK* with a 33-bp insertion.

**Patients with EML4-ALK fusion-positive NSCLCs**

Out of 313 patients, 5 (1.6%) had tumors that contained *EML4-ALK* fusion genes. These five fusion-positive tumors were adenocarcinomas, and the clinicopathologic profiles of the five
fusion-positive vs. negative adenocarcinoma patients are shown in Table 2. No patients with

*EML4-ALK* fusion-positive tumors had received any induction chemotherapy, because their
clinical stages had been evaluated as 1A to 2A. Two fusion-positive adenocarcinomas were
detected from pathological stage 1A tumors and three from stage 3A tumors. Four of the five
patients with fusion-positive tumors were nonsmokers, and the only smoker had a 0.25
pack/year smoking history, which was less than fusion-negative patients that smoked.

**Mutations of the EGFR and KRAS genes in NSCLCs**

Out of 313 samples, *EGFR* mutations were detected in 105 adenocarcinomas and in one
squamous cell carcinoma. *KRAS* mutations were detected in 35 patients: 29 in
adenocarcinomas, three in large cell carcinomas, two in squamous cell carcinomas, and
one in pleomorphic carcinoma. *ERBB2* mutations were detected in seven adenocarcinomas
and in one squamous cell carcinoma (Table 3). All five fusion-positive adenocarcinomas had
wild-type *EGFR*, *KRAS*, and *ERBB2* genes (Table 2). Further, tumors with the *EML4-ALK*
fusion had no *p53* (exons 5-8) gene mutations (data not shown).

**Prognosis and overall survival of the EML4-ALK fusion-harboring patients**

Two patients with p-stage 1A adenocarcinoma received no adjuvant therapy and survived
for over 66 months (patient 1) and 60 months (patient 2) without any recurrence or
metastasis (Table 1). A patient with p-stage 3A adenocarcinoma (patient 3) underwent a
right upper lobectomy, followed by two cycles of combined adjuvant chemotherapy with a carboplatin plus paclitaxel regimen. A metastatic lesion appeared in the remaining middle lobe, and a right middle lobectomy was performed 73 months after the primary lung resection. Histopathological studies determined that the tumor in the resected right middle lobe and the anterior mediastinal lymph node (#3a) were a recurrent tumor and metastatic lymph node of the primary tumor. Additional RT-PCR assays revealed that the relapsed tumor cells in the right middle lobe harbored the same EML4-ALK fusion. Histopathological studies demonstrated that this second tumor had the same characteristics as the primary resected tumor. With 100 mg/day of S-1 (Tegafur/ Gimeracil/ Oteracil) medication, patient 3 survived for over 99 months following the first pulmonary resection (26 months after the second resection).

Two patients with p-stage 3A adenocarcinoma (patients 4 and 5) underwent a left upper lobectomy and a left lower lobectomy, respectively. Patient 4 underwent two cycles of adjuvant chemotherapy with the carboplatin plus paclitaxel regimen. Multiple brain metastases appeared 16 months after the pulmonary resection, and whole brain radiation therapy (30 Gy/ 10 fractures) was performed. Patient 4 died 28 months after the operation. Eight months after the lobectomy, chest CT studies revealed that patient 5 had a metastatic nodule in the right lower lung and metastatic lymph nodes in the left mediastinum. This
patient underwent two cycles of chemotherapy with the carboplatin plus paclitaxel regimen. Seventeen months after the resection, a metastatic lesion was found in the brain. Patient 5 then underwent gamma knife radio-surgery with vinorelbine. Metastatic lesions in the mediastinum and liver grew, and patient 5 died 53 months after the pulmonary resection.

**Histopathological analysis of EML4-ALK fusion-harboring tumors**

One of the five fusion-harboring adenocarcinomas was an acinar adenocarcinoma, and the other four were classified as mixed subtype adenocarcinomas: two of the acinar predominant subtype and two of the papillary predominant subtype. The four adenocarcinomas of mixed subtype were evaluated as poorly differentiated (Grade 3), and the acinar adenocarcinoma was graded as moderately differentiated (Grade 2) (Fig. 3).

[Discussion]

Using RT-PCR analysis, we detected five *EML4-ALK* fusion genes from among 313 NSCLC specimens (1.6%). The frequency rates for *EML4-ALK* fusions in NSCLCs have been reported in several studies, and our results are comparable with the previously published data. In our study, samples were collected entirely from a Japanese population; the frequency of *EML4-ALK* fusions was similar to that of U.S. plus Korean, European, or
Chinese\textsuperscript{37} populations. This finding suggests that there is no significant difference in the frequency of \textit{EML4-ALK} fusion genes between countries.

The prognosis and the clinical course after primary tumor resection of our patients with \textit{EML4-ALK} fusion-harboring NSCLC seemed to be relatively favorable. Both of the patients with pathological grade 1A adenocarcinomas survived for over 60 months without any recurrence or metastasis. One with a pathological grade 3A adenocarcinoma (Patient 2) survived for over 99 months, with pulmonary metastasis occurring 73 months after the primary lung resection. This case showed that an \textit{EML4-ALK} fusion positive tumor could relapse after a long interval (>60 months), but adequate local and systemic control could provide an excellent survival benefit. One patient with a pathological grade 3A adenocarcinoma had brain metastasis 8 months after the operation, yet still survived 53 months. Inamura and colleagues (2007) reported six patients with pathological grade 1A adenocarcinomas and two patients with grade 3A adenocarcinomas who survived over 59.0 ± 8.8 months and 39 ± 6.9 months, respectively.\textsuperscript{35} Because there are not enough clinical data dealing with fusion-harboring patients thus far, it is difficult to appreciate the prognosis of \textit{EML4-ALK} fusion-positive patients statistically. However, considering the Inamura and colleagues (2007) report and our data, genetic alterations producing \textit{EML4-ALK} fusions may not be an unfavorable prognostic factor for adenocarcinoma patients.
We investigated the incidence of \textit{EML4-ALK} in this relatively large-scale screen and analyzed its characteristics according to the age, sex, and smoking habits of the patients, as well as the histology, differentiation, and p-stage of the tumors. Of the five \textit{EML4-ALK} fusion-harboring adenocarcinoma patients, four were female. The fusion-positive patients were mostly non-smokers; only one patient had a smoking history of a 0.25 pack/year. It should be noted that the pack/year number of fusion-positive patients was smaller than that of fusion-negative patients (Table 2; 0.05 ± 0.01 vs. 29.6 ± 36.6, \( p < 0.001 \)).

All five fusions were detected only in adenocarcinomas (Table 3). These findings may indicate that the \textit{EML4-ALK} fusion gene is related to the oncogenes that have been mutated in some nonsmokers' lung adenocarcinomas. This tendency is compatible with several previously reported results.\textsuperscript{25, 35, 37} This finding also suggests the importance of patient selection for gene-targeted therapy using ALK kinase inhibitors, because the efficiency of tyrosine kinase inhibition is strongly related to typical clinicopathologic backgrounds, as is recognized for the use of gefitinib and erlotinib. Our data and that of previous investigators indicate the specific clinicopathologic features of candidates for ALK tyrosine kinase inhibitor therapy.

As shown in this and other studies,\textsuperscript{10-12, 24, 28, 38-45} about half of Japanese lung adenocarcinomas harbor a mutation in \textit{EGFR}, 10-15\% in \textit{KRAS}, and 4-6\% in \textit{ERBB2}. Our
genetic analysis of the *EGFR*, *KRAS* and *ERBB2* genes demonstrated that the *EML4-ALK* fusion gene is mutually exclusive with mutations in these genes. Therefore, two-thirds of lung adenocarcinomas are classified based on the genetic alterations of their tyrosine kinase, which indicates that most adenocarcinomas are candidates for gene-targeted therapy, especially therapy involving tyrosine kinase inhibitors.

Usually, gefitinib or erlotinib therapy has been applied to control locally advanced or metastatic adenocarcinomas after several regimens of chemotherapy. Up to the present, most of adenocarcinoma treated with these tyrosine kinase inhibitors have not been confirmed their *EGFR* gene status because screening for mutations in the *EGFR* has not been practical due to financial problems and/or technical inconvenience. According to the findings from many researchers and our study, good responders to gefitinib or erlotinib can be estimated to harbor mutations in the *EGFR* gene and not the *EML4-ALK* fusions. At present, as gefitinib or erlotinib are usually applied for certain adenocarcinoma patient groups with specific clinical characteristics (e.g., Asian, female, and non-smokers), their efficiency are getting more favorable. Nevertheless, some non-responders would be left and a certain number of *EML4-ALK* fusion-harboring adenocarcinomas would hide behind them. Therefore, we considered that it would be very beneficial to demonstrate RT-PCR assays for detection of the *EML4-ALK* fusions in tumors of the non-responders to such conventional
EGFR kinase inhibitors. We believe this easy and economical screening method and the future ALK kinase targeted therapy would be very significant for treatment of the EML4-ALK fusion-harboring adenocarcinomas.

Nine EML4-ALK variants have been previously identified by other investigators: 1, 2, 3a, 3b, 4, 5a, 5b, 6, and 7. Variants 1, 2, 3a, and 5a consist of a simple fusion between an exon of EML4 (exons 13, 20, 6, and 2, respectively) and exon 20 of the ALK gene. Variant 3b involves a 33-bp insertion between exon 6 of EML4 and exon 20 of ALK, and variant 5b involves a 117-bp insertion between exon 2 of EML4 and exon 20 of ALK. In variant 4, the EML4 exon 14 is fused via an 11-bp insertion to the 50th nucleotide of ALK exon 20. EML4 exon 13 is fused 69-bp upstream of ALK exon 20 in variant 6, and EML4 exon 14 is fused to nucleotide 13 of ALK exon 20 in variant 7.46 Here, we have identified two novel EML4-ALK fusion variants. In the tumor of patient 4, EML4 exon 20 was fused via an 18-bp sequence to ALK exon 20. The inserted sequence of this variant comprises the last 18-bp of ALK intron 19. Thus, this fusion can be classified as a subtype of variant 2. Compared with variant 2, the fusion sequence of patient 5 had a 275-bp deletion of full length of EML4 exon 18 (89-bp), exon 19 (98-bp), and exon 20 (88-bp), and a 68-bp insertion. Therefore, the fusion from patient 5 had a 207-bp smaller sequence than variant 2, which does not provide frame shift. This type of fusion was unique, because it contained mixed sequences from ALK
introns between the *EML4* and *ALK* exons. The characteristic phenomenon of this variant was that the inserted sequences were composed of three *ALK* intron sequences. We could not find *ALK* intron components in the other types of variants containing inserted sequence between *EML4* and *ALK*. Above all, the most peculiar features of the fusion gene from patient 5 were eleven sequences identical to the first 14-bp, and another 42 of 15-bp, *ALK* intron sequences and their reversed sequences. Reversed sequences were correlated with the existence of identical sequences on anti-sense DNA, scattered around the *ALK* introns. There is no confirmed evidence, but this uncommon event of quite a number of duplicated sequences may induce altered *EML4-ALK* fusion conformation. Unfortunately, due to the small number of *EML4-ALK* fusion samples, the influence of fusion variations on clinicopathologic features remains unknown.

According to the WHO classification of lung tumors (2004), adenocarcinomas can be classified as acinar and papillary adenocarcinomas, bronchioloalveolar carcinoma, solid adenocarcinoma with mucin production, mixed subtype adenocarcinomas, and their variants. In our study, one fusion-positive sample was an acinar carcinoma, and four were adenocarcinomas of mixed subtype (two of the acinar predominant type and two of the papillary predominant type). Inamura and colleagues (2009) reported the detection of five fusion-positive adenocarcinomas out of 206 papillary predominant subtypes and six out of
34 acinar predominant subtypes, showing a significantly higher tendency for fusions in acinar-predominant subtype adenocarcinomas. Considering these findings, \textit{EML4-ALK} fusion-harboring adenocarcinomas are likely to be related to acinar components.

In conclusion, we determined that \textit{EML4-ALK} fusion-harboring lung cancers were only present in adenocarcinomas and in patients with little or no smoking history in our test group.

In addition, we concluded that the \textit{EML4-ALK} fusions were mutually exclusive with mutations in the \textit{EGFR}, \textit{KRAS}, and \textit{ERBB2} genes. These observations provide additional information on favorable responders with respect to specific ALK kinase inhibitor therapy.

\section*{Acknowledgements}

We thank Ms. Seiko Sakai for excellent secretarial assistance. This project was not supported by any outside funds.

\section*{References}


[Figure legends]

Figure 1A

RT-PCR studies using the EML4 (exon 2)-ALK primer set. The λ DNA-HindIII Digest (BioLabs) and the φX174 HaeIII digest (Takara Bio) were used as the DNA ladder markers. In each patient (1-5), a single band was amplified, and its size was subsequently determined: 1357-2027 bp band in patient 1, 603-872 bp band in patient 2, 603-872 bp band in patient 3, 2027-2322 bp band in patient 4, and 2027-2322 bp band in patient 5.

Figure 1B
RT-PCR studies using the EML4 (exon13)-ALK primer set. The same DNA ladder markers as above were used. A single band was amplified in three of the five patients, and the sizes were subsequently determined: a <281 bp band in patient 1, 872-1078 bp band in patient 4, and 603-872bp band in patient 5. No RT-PCR products were obtained in patients 2 and 3.

**Figure 2A**

Schema showing two novel EML4-ALK fusion variants and variant 2. In patient 4, exon 20 of EML4 is fused via an 18-bp sequence to exon 20 of ALK. This fusion could be classified as a subtype of variant 2. In patient 5, exon 17 of EML4 is fused via a 68-bp insertion to exon 20 of ALK. Compared with variant 2, this fusion type had a full length deletion EML4 exon 18-20 (275-bp) and a 68-bp insertion. This results in a 207-bp shorter fusion sequence than variant 2, which provided no frame shift.

**Figure 2B**

Schema showing the fusion pattern of patient 4 with precise sequence information. The inserted sequence was identical to the last part of ALK intron 19, which indicates that the break point of ALK is 18-bp upstream of that in variant 2.

**Figure 2C**

Schema showing the location of identical sequences composing inserted sequences. Three parts of the inserted sequence are named A, B, and C. Sequences marked as "A" and a left
arrow indicate the sequence 5’-AGTCTTGCTCTGTC-3’, and those marked as “A” and a
right arrow indicate the reversed sequence 5’-GACAGAGCAAGACT-3’. Sequences
marked as “B” with a left arrow indicate the sequence 5’-TCCCAGGCTGGAGTGCAGT-3’,
and those marked by “B” with a right arrow indicate the reversed sequence. Sequence
marked as “C” with a left arrow indicates the 35-bp sequence
5’-GGCAATTACACATTTCATTCATTGCATCCTCAG-3’.

**Figure 3**

Histopathological studies of *EML4-ALK* fusion-harboring tumors. All of the carcinomas were
adenocarcinomas. One was an acinar adenocarcinoma (patient 2), and the other four were
classified as adenocarcinomas of mixed subtypes. In patients 3 and 4, acinar characteristics
were evaluated to be predominant. The acinar adenocarcinoma in patient 2 was classified
as moderately differentiated, and the others were all classified as poorly differentiated
(grade 3) types.
<table>
<thead>
<tr>
<th>Pt</th>
<th>Age</th>
<th>Sex</th>
<th>Histology and Subtype of Adenocarcinomas</th>
<th>Predominant subtype</th>
<th>diff.</th>
<th>p-stage</th>
<th>Tumor location</th>
<th>EML4-ALK variants</th>
<th>Smoking (pack-year)</th>
<th>Overall survival (M)</th>
<th>Prognosis</th>
<th>Disease-free survival (M)</th>
<th>Site of recurrence</th>
<th>EGFR mutation</th>
<th>KRAS mutation</th>
<th>ERBB2 mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>77</td>
<td>F</td>
<td>Ad with mixed subtypes</td>
<td>Papillary</td>
<td>Poor</td>
<td>1A</td>
<td>LUL</td>
<td>V1</td>
<td>0</td>
<td>66M</td>
<td>alive</td>
<td>66M</td>
<td>none</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2</td>
<td>72</td>
<td>F</td>
<td>Acinar Ad</td>
<td>Acinar</td>
<td>Mod</td>
<td>1A</td>
<td>LUL</td>
<td>V2b</td>
<td>0</td>
<td>66M</td>
<td>alive</td>
<td>66M</td>
<td>none</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>53</td>
<td>M</td>
<td>Ad with mixed subtypes</td>
<td>Acinar</td>
<td>Poor</td>
<td>3A</td>
<td>RUL</td>
<td>V3a</td>
<td>0.25</td>
<td>98M</td>
<td>alive</td>
<td>73M</td>
<td>lung</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4</td>
<td>75</td>
<td>F</td>
<td>Ad with mixed subtypes</td>
<td>Acinar</td>
<td>Poor</td>
<td>3A</td>
<td>LUL</td>
<td>novel type</td>
<td>0</td>
<td>28M</td>
<td>dead</td>
<td>16M</td>
<td>brain</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>5</td>
<td>73</td>
<td>F</td>
<td>Ad with mixed subtypes</td>
<td>Papillary</td>
<td>Poor</td>
<td>3A</td>
<td>LLL</td>
<td>novel type</td>
<td>0</td>
<td>53M</td>
<td>dead</td>
<td>8M</td>
<td>brain</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Pt, patient; Ad, adenocarcinoma; diff, differentiation; Mod, moderately differentiated; p-stage, pathological stage; LUL, left upper lobe; RUL, right upper lobe; RLL, right lower lobe; LLL, left lower lobe; V, EML4-ALK variant; M, months; -, not detected
Table 2. Clinicopathologic and Genetic Comparisons Between EML4-ALK Fusion-positive and -negative Adenocarcinomas

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>EML4-ALK fusion</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>(+) (n=5)</td>
<td>(-) (n=206)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (yr; mean)</td>
<td>70.0 ± 9.7</td>
<td>65.2 ± 10.1</td>
<td>0.29</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>111</td>
<td>1</td>
<td>110</td>
<td>0.31</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>100</td>
<td>4</td>
<td>96</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>92</td>
<td>4</td>
<td>88</td>
<td>0.58</td>
<td></td>
</tr>
<tr>
<td>Smoker</td>
<td>119</td>
<td>1</td>
<td>118</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pack-year (mean ± SD)</td>
<td>0.05 ± 0.11</td>
<td>29.6 ± 36.6</td>
<td>p&lt;0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Differentiation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well</td>
<td>87</td>
<td>0</td>
<td>86</td>
<td>p&lt;0.01†</td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>91</td>
<td>1</td>
<td>87</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poor</td>
<td>33</td>
<td>4</td>
<td>33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-Stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>141</td>
<td>2</td>
<td>139</td>
<td>0.16‡</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>20</td>
<td>0</td>
<td>20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>42</td>
<td>3</td>
<td>39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>8</td>
<td>0</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EGFR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wild type</td>
<td>106</td>
<td>5</td>
<td>101</td>
<td>0.072</td>
<td></td>
</tr>
<tr>
<td>Mutated</td>
<td>105</td>
<td>0</td>
<td>105</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KRAS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wild type</td>
<td>182</td>
<td>5</td>
<td>177</td>
<td>0.81</td>
<td></td>
</tr>
<tr>
<td>Mutated</td>
<td>29</td>
<td>0</td>
<td>29</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ERBB2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wild type</td>
<td>204</td>
<td>5</td>
<td>199</td>
<td>0.40</td>
<td></td>
</tr>
<tr>
<td>Mutated</td>
<td>7</td>
<td>0</td>
<td>7</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

† well plus moderately differentiated adenocarcinomas vs. poorly differentiated adenocarcinomas; ‡ p-I plus II adenocarcinomas vs. p-III plus IV adenocarcinomas
### Table 3. Characteristics of Patients Included in This Study

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Histology</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adenocarcinoma</td>
<td>Squamous cell carcinoma</td>
<td>Others</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(n=211)</td>
<td>(n=75)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (yr; mean)</td>
<td>65.3</td>
<td>69.6</td>
<td>64.0</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>202</td>
<td>111</td>
<td>66</td>
<td>25</td>
</tr>
<tr>
<td>Female</td>
<td>111</td>
<td>100</td>
<td>9</td>
<td>2</td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>97</td>
<td>92</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Smoker (ex- / current)</td>
<td>216</td>
<td>119</td>
<td>72</td>
<td>25</td>
</tr>
<tr>
<td>Pack-year (mean ± SD)</td>
<td>28.9 ± 46.6</td>
<td>60.1 ± 37.1</td>
<td>54.2 ± 33.8</td>
<td></td>
</tr>
<tr>
<td>Differentiation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well</td>
<td>91</td>
<td>87</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Moderate</td>
<td>143</td>
<td>91</td>
<td>52</td>
<td>4</td>
</tr>
<tr>
<td>Poor</td>
<td>80</td>
<td>33</td>
<td>20</td>
<td>21</td>
</tr>
<tr>
<td>p-Stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>197</td>
<td>141</td>
<td>43</td>
<td>13</td>
</tr>
<tr>
<td>II</td>
<td>37</td>
<td>20</td>
<td>13</td>
<td>4</td>
</tr>
<tr>
<td>III</td>
<td>70</td>
<td>42</td>
<td>19</td>
<td>9</td>
</tr>
<tr>
<td>IV</td>
<td>9</td>
<td>8</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>EGFR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wild type</td>
<td>207</td>
<td>106</td>
<td>74</td>
<td>27</td>
</tr>
<tr>
<td>Mutated</td>
<td>106</td>
<td>105</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>KRAS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wild type</td>
<td>278</td>
<td>182</td>
<td>73</td>
<td>23</td>
</tr>
<tr>
<td>Mutated</td>
<td>35</td>
<td>29</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>ERBB2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wild type</td>
<td>305</td>
<td>204</td>
<td>74</td>
<td>27</td>
</tr>
<tr>
<td>Mutated</td>
<td>8</td>
<td>7</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>EML4-ALK fusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>negative</td>
<td>308</td>
<td>206</td>
<td>75</td>
<td>27</td>
</tr>
<tr>
<td>positive</td>
<td>5</td>
<td>5</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
RT-PCR studies using the *EML4* (exon 2)-*ALK* primer set. The λ DNA-*HindIII* Digest (BioLabs) and the φX174 *HaeIII* digest (Takara Bio) were used as the DNA ladder markers.

In each patient (1-5), a single band was amplified, and its size was subsequently determined: 1357-2027 bp band in patient 1, 603-872 bp band in patient 2, 603-872 bp band in patient 3, 2027-2322 bp band in patient 4, and 2027-2322 bp band in patient 5.
RT-PCR studies using the \textit{EML4} (exon13)-\textit{ALK} primer set. The same DNA ladder markers as above were used. A single band was amplified in three of the five patients, and the sizes were subsequently determined: a <281 bp band in patient 1, 872-1078 bp band in patient 4, and 603-872bp band in patient 5. No RT-PCR products were obtained in patients 2 and 3.
Scheme showing two novel EML4-ALK fusion variants and variant 2. In patient 4, exon 20 of EML4 is fused via an 18-bp sequence to exon 20 of ALK. This fusion could be classified as a subtype of variant 2. In patient 5, exon 17 of EML4 is fused via a 68-bp insertion to exon 20 of ALK. Compared with variant 2, this fusion type had a full length deletion EML4 exon 18-20 (275-bp) and a 68-bp insertion. This results in a 207-bp shorter fusion sequence than variant 2, which provided no frame shift.
Schema showing the fusion pattern of patient 4 with precise sequence information. The inserted sequence was identical to the last part of ALK intron 19, which indicates that the break point of ALK is 18-bp upstream of that in variant 2.
Schema showing the location of identical sequences composing inserted sequences. Three parts of the inserted sequence are named A, B, and C. Sequences marked as “A” and a left arrow indicate the sequence 5’-AGTCTTGCTCTGTC-3’, and those marked as “A” and a right arrow indicate the reversed sequence 5’-GACAGAGCAAGACT-3’. Sequences marked as “B” with a left arrow indicate the sequence 5’-TCCCAGGCTGGAGTGCAGT-3’, and those marked by “B” with a right arrow indicate the reversed sequence. Sequence marked as “C” with a left arrow indicates the 35-bp sequence

5’-GGCAATTTACACATTCAATTCATTCGATCCTCAG-3’.
Histopathological studies of *EML4-ALK* fusion-harboring tumors. All of the carcinomas were adenocarcinomas. One was an acinar adenocarcinoma (patient 2), and the other four were classified as adenocarcinomas of mixed subtypes. In patients 3 and 4, acinar characteristics were evaluated to be predominant. The acinar adenocarcinoma in patient 2 was classified as moderately differentiated, and the others were all classified as poorly differentiated (grade 3) types.